96 related articles for article (PubMed ID: 7529428)
1. The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Chisholm GD; Hedlund PO; Adolfsson J; Denis LJ; Friberg S; Johansson JE; Peeling B
Scand J Urol Nephrol Suppl; 1994; 162():107-14; discussion 115-27. PubMed ID: 7529428
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Schröder F; Tribukait B; Böcking A; DeVere White R; Koss L; Lieber M; Stenkvist B; Zetterberg A
Scand J Urol Nephrol Suppl; 1994; 162():51-63; discussion 15-27. PubMed ID: 7529429
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
5. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.
Grignon DJ; Hammond EH
Arch Pathol Lab Med; 1995 Dec; 119(12):1122-6. PubMed ID: 7503660
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
8. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
10. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
[TBL] [Abstract][Full Text] [Related]
12. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Zagars GK; Pollack A; von Eschenbach AC
Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
[TBL] [Abstract][Full Text] [Related]
15. [Can the tumor stage of prostate carcinoma be determined with the aid of prostate-specific antigen?].
Semjonow A; Hertle L
Urologe A; 1995 Jul; 34(4):290-6. PubMed ID: 7545843
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
17. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
18. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H
J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775
[TBL] [Abstract][Full Text] [Related]
19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]